AAAAAA

   
Results: 1-19 |
Results: 19
THE ROLE OF GOVERNMENT AND PRIVATE INSURERS IN GUIDING AND IMPLEMENTING PHARMACOECONOMIC ANALYSES
Authors: FREUND DA LUCE BR
Citation: Da. Freund et Br. Luce, THE ROLE OF GOVERNMENT AND PRIVATE INSURERS IN GUIDING AND IMPLEMENTING PHARMACOECONOMIC ANALYSES, PharmacoEconomics, 13(4), 1998, pp. 383-387
TECHNOLOGY-ASSESSMENT OF MEDICAL DEVICES
Authors: RAMSEY SD LUCE BR
Citation: Sd. Ramsey et Br. Luce, TECHNOLOGY-ASSESSMENT OF MEDICAL DEVICES, American journal of managed care, 4, 1998, pp. 113-114
THE LIMITED STATE OF TECHNOLOGY-ASSESSMENT FOR MEDICAL DEVICES - FACING THE ISSUES
Authors: RAMSEY SD LUCE BR DEYO R FRANKLIN G
Citation: Sd. Ramsey et al., THE LIMITED STATE OF TECHNOLOGY-ASSESSMENT FOR MEDICAL DEVICES - FACING THE ISSUES, American journal of managed care, 4, 1998, pp. 188-199
PHARMACOECONOMICS AND MANAGED CARE - METHODOLOGIC AND POLICY ISSUES
Authors: LUCE BR
Citation: Br. Luce, PHARMACOECONOMICS AND MANAGED CARE - METHODOLOGIC AND POLICY ISSUES, Medical decision making, 18(2), 1998, pp. 4-11
GUIDELINES FOR PHARMACOECONOMIC STUDIES - RECOMMENDATIONS FROM THE PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE
Authors: SIEGEL JE TORRANCE GW RUSSELL LB LUCE BR WEINSTEIN MC GOLD MR
Citation: Je. Siegel et al., GUIDELINES FOR PHARMACOECONOMIC STUDIES - RECOMMENDATIONS FROM THE PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE, PharmacoEconomics, 11(2), 1997, pp. 159-168
WHEN IS A COST-EFFECTIVENESS CLAIM VALID - HOW MUCH SHOULD THE FDA CARE
Authors: LUCE BR HILLMAN AL
Citation: Br. Luce et Al. Hillman, WHEN IS A COST-EFFECTIVENESS CLAIM VALID - HOW MUCH SHOULD THE FDA CARE, American journal of managed care, 3(11), 1997, pp. 1660-1666
PRODUCTIVITY COSTS, TIME COSTS AND HEALTH-RELATED QUALITY-OF-LIFE - ARESPONSE TO THE ERASMUS GROUP
Authors: WEINSTEIN MC SIEGEL JE GARBER AM LIPSCOMB J LUCE BR MANNING WG TORRANCE GW
Citation: Mc. Weinstein et al., PRODUCTIVITY COSTS, TIME COSTS AND HEALTH-RELATED QUALITY-OF-LIFE - ARESPONSE TO THE ERASMUS GROUP, Health economics, 6(5), 1997, pp. 505-510
MANAGED CARE PHARMACY, SOCIOECONOMIC ASSESSMENTS AND DRUG ADOPTION DECISIONS
Authors: LYLES A LUCE BR RENTZ AM
Citation: A. Lyles et al., MANAGED CARE PHARMACY, SOCIOECONOMIC ASSESSMENTS AND DRUG ADOPTION DECISIONS, Social science & medicine, 45(4), 1997, pp. 511-521
NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM WORKING GROUP-REPORTON THE COST-EFFECTIVENESS OF ASTHMA CARE
Authors: SULLIVAN S ELIXHAUSER A BUIST AS LUCE BR EISENBERG J WEISS KB
Citation: S. Sullivan et al., NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM WORKING GROUP-REPORTON THE COST-EFFECTIVENESS OF ASTHMA CARE, American journal of respiratory and critical care medicine, 154(3), 1996, pp. 84-95
THE VIEW FROM MANAGED CARE PHARMACY
Authors: LUCE BR LYLES CA RENTZ AM
Citation: Br. Luce et al., THE VIEW FROM MANAGED CARE PHARMACY, Health affairs, 15(4), 1996, pp. 168-176
WORKING TOWARD A COMMON CURRENCY - IS STANDARDIZATION OF COST-EFFECTIVENESS ANALYSIS POSSIBLE
Authors: LUCE BR
Citation: Br. Luce, WORKING TOWARD A COMMON CURRENCY - IS STANDARDIZATION OF COST-EFFECTIVENESS ANALYSIS POSSIBLE, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 19-22
PHARMACEUTICAL REGULATION IN SPAIN - RESPONSE
Authors: HUTTON J LUCE BR
Citation: J. Hutton et Br. Luce, PHARMACEUTICAL REGULATION IN SPAIN - RESPONSE, Health affairs, 14(1), 1995, pp. 323-323
THE USE OF TECHNOLOGY-ASSESSMENT BY HOSPITALS, HEALTH MAINTENANCE ORGANIZATIONS, AND 3RD-PARTY PAYERS IN THE UNITED-STATES
Authors: LUCE BR BROWN RE
Citation: Br. Luce et Re. Brown, THE USE OF TECHNOLOGY-ASSESSMENT BY HOSPITALS, HEALTH MAINTENANCE ORGANIZATIONS, AND 3RD-PARTY PAYERS IN THE UNITED-STATES, International journal of technology assessment in health care, 11(1), 1995, pp. 79-92
METHODS OF COST-EFFECTIVENESS ANALYSIS - AREAS OF CONSENSUS AND DEBATE
Authors: LUCE BR SIMPSON K
Citation: Br. Luce et K. Simpson, METHODS OF COST-EFFECTIVENESS ANALYSIS - AREAS OF CONSENSUS AND DEBATE, Clinical therapeutics, 17(1), 1995, pp. 109-125
METHODS OF PHARMACOECONOMIC EVALUATION OF NEW MEDICAL TREATMENTS IN PSYCHIATRY
Authors: REVICKI DA LUCE BR
Citation: Da. Revicki et Br. Luce, METHODS OF PHARMACOECONOMIC EVALUATION OF NEW MEDICAL TREATMENTS IN PSYCHIATRY, Psychopharmacology bulletin, 31(1), 1995, pp. 57-65
RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR LYMPHOID CANCER - AN ECONOMIC-ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Authors: LUCE BR SINGER JW WESCHLER JM BUCKNER CD SHEINGOLD SH SHANNONDORCY K APPELBAUM FR NEMUNAITIS J
Citation: Br. Luce et al., RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR LYMPHOID CANCER - AN ECONOMIC-ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, PharmacoEconomics, 6(1), 1994, pp. 42-48
THE PHARMACEUTICAL-INDUSTRY AND HEALTH REFORM - LESSONS FROM EUROPE
Authors: HUTTON J BOROWITZ M OLEKSY I LUCE BR
Citation: J. Hutton et al., THE PHARMACEUTICAL-INDUSTRY AND HEALTH REFORM - LESSONS FROM EUROPE, Health affairs, 13(3), 1994, pp. 98-111
COST-ANALYSIS OF IMIPENEM-CILASTATIN VERSUS CLINDAMYCIN WITH TOBRAMYCIN IN THE TREATMENT OF ACUTE INTRAABDOMINAL INFECTION
Authors: DELISSOVOY G ELIXHAUSER A LUCE BR WESCHLER J MOWERY P REBLANDO J SOLOMKIN J
Citation: G. Delissovoy et al., COST-ANALYSIS OF IMIPENEM-CILASTATIN VERSUS CLINDAMYCIN WITH TOBRAMYCIN IN THE TREATMENT OF ACUTE INTRAABDOMINAL INFECTION, PharmacoEconomics, 4(3), 1993, pp. 203-214
HEALTH-CARE CBA CEA - AN UPDATE ON THE GROWTH AND COMPOSITION OF THE LITERATURE
Authors: ELIXHAUSER A LUCE BR TAYLOR WR REBLANDO J
Citation: A. Elixhauser et al., HEALTH-CARE CBA CEA - AN UPDATE ON THE GROWTH AND COMPOSITION OF THE LITERATURE, Medical care, 31(7), 1993, pp. 101900001-101900011
Risultati: 1-19 |